Ithaka Group LLC Vertex Pharmaceuticals Inc Transaction History

Ithaka Group LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 12, 2019	SELL	$166.23 - $187.09 $8.12 Million - $9.13 Million	-48,826 Closed	0 $0
Q2 2019 Aug 12, 2019	SELL	$164.61 - $190.37 $19,259 - $22,273	-117 Reduced 0.24%	48,826 $8.95 Million
Q1 2019 May 13, 2019	SELL	$163.73 - $194.7 $57,632 - $68,534	-352 Reduced 0.71%	48,943 $9 Million
Q4 2018 Feb 14, 2019	SELL	$151.91 - $192.21 $174,848 - $221,233	-1,151 Reduced 2.28%	49,295 $8.17 Million
Q3 2018 Nov 13, 2018	SELL	$167.73 - $192.74 $609,530 - $700,417	-3,634 Reduced 6.72%	50,446 $9.72 Million
Q2 2018 Aug 13, 2018	SELL	$145.72 - $169.96 $122,841 - $143,276	-843 Reduced 1.53%	54,080 $9.19 Million
Q1 2018 May 14, 2018	SELL	$151.6 - $177.13 $212,240 - $247,982	-1,400 Reduced 2.49%	54,923 $8.95 Million
Q4 2017 Feb 06, 2018	BUY	$137.28 - $155.55 $3.12 Million - $3.53 Million	22,715 Added 67.59%	56,323 $8.44 Million
Q3 2017 Nov 13, 2017	BUY	$148.13 - $162.24 $4.98 Million - $5.45 Million	33,608	33,608 $5.11 Million

1,707

226M

1.2M

1.59M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $120B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Ithaka Group LLC, based on Form 13F filings with the SEC.

Stay updated on Ithaka Group LLC with notifications on news.